Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 353 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: bupropion hydrochloride Clear all
Recruiting Phase 3 Interventional Accepts healthy volunteers

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

NCT05732272
View directory record Official record
Conditions
Smoking Cessation
Interventions
Bupropion
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence

NCT00304707
View directory record Official record
Conditions
Smoking Cessation, Alcohol-Related Disorders
Interventions
Bupropion, placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation

NCT00670904
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking
Interventions
Pharmacist-delivered group program for smoking cessation, Brief standard care session for smoking cessation delivered over the telephone
Other
Lead sponsor
University of Montana
Other
Eligibility
21 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 2 Interventional

Mechanistic Evaluation of Response in TRD (MERIT)

NCT04608396
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 3 Interventional

Bupropion for Hospital-Based Smoking Cessation

NCT00261170
View directory record Official record
Conditions
Smoking
Interventions
bupropion, placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 23, 2008 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 4 Interventional

Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)

NCT00917059
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Bupropion XL
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bupropion Alone or Combined With Nicotine Gum

NCT01621022
View directory record Official record
Conditions
Tobacco Dependence
Interventions
bupropion + nicotine gum, Active bupropion-Placebo gum, Placebo bupropion-Placebo gum
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions

NCT00865462
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 6, 2026, 9:50 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
39
States / cities
Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety

NCT01857596
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined), Sexual Interest/Arousal Disorder (DSM-5 Defined)
Interventions
bupropion, Lorexys low-dose, Lorexys moderate-dose
Drug
Lead sponsor
S1 Biopharma, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Beachwood, Ohio • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1

NCT00136747
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Memantine, bupropion, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 2 Interventional

Combination Pharmacotherapy for Smoking Cessation Among Methadone Patients

NCT00060814
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Combined intervention
Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00404755
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia
Interventions
escitalopram, bupropion, imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.

NCT00991081
View directory record Official record
Conditions
Smoking
Interventions
Counseling, Self-help guide, Pharmacotherapy, Genetic feedback, verbal, Genetic feedback, printed
Behavioral · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Menlo Park, California • Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns

NCT02078180
View directory record Official record
Conditions
Depression
Interventions
generic bupropion
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Individualizing Pharmacotherapy for African American Smokers

NCT03897439
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine patch, Varenicline Tartrate, Bupropion
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Voxelotor CYP and Transporter Cocktail Interaction Study

NCT05981365
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

NCT00863941
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3

NCT00136786
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

An Open Label Trial of Bupropion and Naltrexone for Binge Drinking

NCT02842073
View directory record Official record
Conditions
Binge Drinking
Interventions
Naltrexone, Bupropion
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 34 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

NCT00687713
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Bupropion, Placebo
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 6, 2026, 9:50 AM EDT
Completed No phase listed Observational Results available

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

NCT06090461
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 6, 2026, 9:50 AM EDT
Active, not recruiting No phase listed Observational

Anti-obesity Pharmacotherapy and Inflammation

NCT05756764
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
35 Years to 60 Years
Enrollment
30 participants
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 6, 2026, 9:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

NCT03539900
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 6, 2026, 9:50 AM EDT